(BRK.A), (BRK.B)
Berkshire Hathaway has solidified its relationship with DaVita, a prominent global healthcare company specializing in kidney care. With Berkshire holding just under 40 percent ownership in DaVita, a strategic stock buyback agreement has been established to prevent Berkshire from attaining a majority stake in the company.
The Share Repurchase Agreement outlines the terms for maintaining ownership balance. Should Berkshire’s ownership reach at least 45.0% of DaVita’s common stock, the company will engage in quarterly repurchases to adjust Berkshire’s stake back to 45.0%. These repurchases will be executed at the volume-weighted average per share price paid by DaVita during the applicable period. Additionally, if Berkshire’s ownership surpasses 49.5%, immediate share repurchases will be triggered.
Furthermore, Berkshire has agreed to vote shares exceeding 40% in accordance with DaVita’s Board of Directors’ recommendations. This agreement supplements the existing standstill letter agreement between the two parties, ensuring alignment with DaVita’s governance structure.
DaVita’s presence extends across the United States and ten other countries, bolstering its stature in the healthcare sector. Berkshire’s substantial investment in DaVita, holding over 36 million shares as of December 31, 2023, underscores its confidence in the company’s growth prospects.
The investment has proven lucrative for Berkshire, as evidenced by DaVita’s recent stock surge to an all-time high. DaVita’s share buyback program has contributed to this success, allowing Berkshire to increase its stake without additional investment.
This strategic agreement highlights the collaborative approach between Berkshire Hathaway and DaVita, ensuring mutual benefit while maintaining a balanced ownership structure.
© 2024 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell a stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.